PHASE I CLINICAL TRIAL OF TEMOZOLOMIDE AND METHOXYAMINE (TRC-102), AN INHIBITOR OF BASE EXCISION REPAIR, IN PATIENTS WITH ADVANCED SOLID TUMORS

PURPOSE: Temozolomide (TMZ) generates DNA adducts that are repaired by direct DNA and base excision repair mechanisms. Methoxyamine (MX, TRC-102) potentiates TMZ activity by binding to apurinic and apyrimidinic (AP) sites after removal of N(3)-methyladenine and N(7)-methylguanine, inhibiting site re...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Invest New Drugs
Glavni autori: Eads, Jennifer R., Krishnamurthi, Smitha S., Saltzman, Joel, Bokar, Joseph A., Savvides, Panos, Meropol, Neal J., Gibbons, Joseph, Koon, Henry, Sharma, Neelesh, Rogers, Lisa, Pink, John J., Xu, Yan, Beumer, Jan H., Riendeau, John, Fu, Pingfu, Gerson, Stanton L., Dowlati, Afshin
Format: Artigo
Jezik:Inglês
Izdano: 2020
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7744386/
https://ncbi.nlm.nih.gov/pubmed/32556884
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-020-00962-x
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items